Memantine misuse and social networks: A content analysis of Internet self‐reports

@article{Natter2020MemantineMA,
  title={Memantine misuse and social networks: A content analysis of Internet self‐reports},
  author={Johan Natter and B. Michel},
  journal={Pharmacoepidemiology and Drug Safety},
  year={2020},
  volume={29},
  pages={1189 - 1193}
}
Memantine is a N‐methyl‐D‐aspartate (NMDA) receptor antagonist currently used for moderate‐to‐severe Alzheimer's disease. Although the risk of memantine abuse is very low, other NMDA receptor antagonists, such as phencyclidine and ketamine, are well known to drug users. The purpose of this study was to collect data on social networks in order to identify unexpected forms of memantine abuse. 
1 Citations

References

SHOWING 1-10 OF 18 REFERENCES
Cognition-enhancing and anxiolytic effects of memantine
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
A review of PCP abuse trends and perceptions.
From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine
...
1
2
...